Pages that link to "Q34360164"
Jump to navigation
Jump to search
The following pages link to BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy (Q34360164):
Displaying 50 items.
- Regulation of glycolysis and gluconeogenesis by acetylation of PKM and PEPCK (Q26825322) (← links)
- The epigenetic basis of diffuse large B-cell lymphoma (Q26852288) (← links)
- Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance (Q26864290) (← links)
- Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review (Q27304386) (← links)
- The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain (Q27681982) (← links)
- Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy (Q28082536) (← links)
- BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy (Q28829626) (← links)
- Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights (Q33983255) (← links)
- Pathogenesis of human B cell lymphomas (Q34245261) (← links)
- Reciprocal occupancy of BCL6 and STAT5 on Growth Hormone target genes: contrasting transcriptional outcomes and promoter-specific roles of p300 and HDAC3. (Q34252584) (← links)
- Ex vivo engineered immune organoids for controlled germinal center reactions (Q35812007) (← links)
- Bcl6 and Maf cooperate to instruct human follicular helper CD4 T cell differentiation (Q35884238) (← links)
- Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy (Q35975127) (← links)
- Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma (Q36042686) (← links)
- The HTLV-1-encoded protein HBZ directly inhibits the acetyl transferase activity of p300/CBP. (Q36106879) (← links)
- Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells (Q36217436) (← links)
- Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas (Q36596874) (← links)
- Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms (Q36703936) (← links)
- Mechanisms of epigenetic deregulation in lymphoid neoplasms (Q36873265) (← links)
- Perspectives and future directions for epigenetics in hematology (Q36962664) (← links)
- Pan-Cancer Analysis of Mutation Hotspots in Protein Domains (Q37170860) (← links)
- A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors (Q37589239) (← links)
- Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. (Q37618835) (← links)
- MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo (Q37699271) (← links)
- Epigenetics and B-cell lymphoma (Q37876151) (← links)
- Emerging epigenetic targets and therapies in cancer medicine (Q38010385) (← links)
- Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictions (Q38022591) (← links)
- Ghrelin O-acyltransferase assays and inhibition (Q38043203) (← links)
- Bag6/Bat3/Scythe: a novel chaperone activity with diverse regulatory functions in protein biogenesis and degradation. (Q38082449) (← links)
- The genetic basis of diffuse large B-cell lymphoma (Q38106812) (← links)
- New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes (Q38110970) (← links)
- Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis (Q38201872) (← links)
- VII. Are lymphomas driven by epigenetic lesions? (Q38523987) (← links)
- Epigenetic Control of B Cell Development and B-Cell-Related Immune Disorders (Q38525405) (← links)
- Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs? (Q38542620) (← links)
- The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target (Q39018438) (← links)
- Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth (Q39023825) (← links)
- A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters (Q39116273) (← links)
- Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015. (Q39221094) (← links)
- Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment? (Q39358270) (← links)
- Immuno-engineered organoids for regulating the kinetics of B-cell development and antibody production. (Q40399099) (← links)
- Heat shock protein 90 inhibitors repurposed against Entamoeba histolytica (Q40613223) (← links)
- Novel therapies for aggressive B-cell lymphoma (Q42011578) (← links)
- Epigenetic approaches for chemosensitization of refractory diffuse large B-cell lymphomas (Q42098536) (← links)
- Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma (Q42630748) (← links)
- Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls (Q46116094) (← links)
- BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells (Q46214552) (← links)
- BCL6 as a therapeutic target for lymphoma (Q47269833) (← links)
- Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway (Q49359645) (← links)
- Generation and characteristics of a novel "double-hit" high grade B-cell lymphoma cell line DH-My6 with / and / gene arrangements and potential molecular targeted therapies (Q57493686) (← links)